Search
Nervgen Pharma Ord Shs
NGENAdd to Watchlist
1.880USD
+0.250+15.34%
Close 11-13 16:00（ET）
202.33MMarket Cap
LossP/E TTM
Nervgen Pharma Ord Shs (NGEN) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Nervgen Pharma Ord Shs in the past month.
Buy
1 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.200USD+717.52%
NGEN Analyst Recommendation Trends
In the current month, NGEN has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NGEN average Analyst price target in the last month is 11.200.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
0
0
0
0
0
6
7
8
8
7
6
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
8
9
8
7
6
1
1
NGEN Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, NGEN EPS is projected to reach -0.107 in FY2026Q3, following reported EPS of -0.223 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.06
-0.09
-0.08
-0.11
-0.13
Actual
-0.27
-0.02
-0.22
--
--
Surprise
-344.55%
+82.27%
-172.79%
--
--
FAQs
What is Nervgen Pharma Ord Shs's price target?
Analysts forecast that Nervgen Pharma Ord Shs's price target is USD 11.20, with the highest forecast at USD 18.00 and the lowest forecast at USD 6.00.
How have Nervgen Pharma Ord ShsNGEN's recent earnings per share performed?
The market expectation was USD -0.22, while Nervgen Pharma Ord ShsNGEN's earnings per share (EPS) for the previous quarter was USD -0.02. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Nervgen Pharma Ord Shs?
Based on the ratings of Nervgen Pharma Ord Shs's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.